	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24
Revenue % growth	1,652.4 0.0%	1,877.4 13.6%	1,597.9 (14.9%)	1,794.9 12.3%	1,814.3 1.1%	2,122.0 17.0%	2,289.5 7.9%	2,237.2 (2.3%)	2,354.6 5.2%	2,264.0 (3.8%)
Cost of Goods Sold (COGS)	0.0	0.0	33.3	136.0	1,019.3	88.1	23.0	5.7	560.7	0.0
Gross Profit % margin	1,652.4 100.0%	1,877.4 100.0%	1,564.7 97.9%	1,658.9 92.4%	794.9 43.8%	2,033.9 95.8%	2,266.5 99.0%	2,231.5 99.7%	1,793.9 76.2%	2,264.0 100.0%
Operating Expenses	790.0	1,086.3	658.2	430.4	(808.9)	527.0	858.7	1,314.3	862.4	971.0
Research & Development Expenses (R&D)	98.4	91.0	117.9	392.6	83.0	26.0	200.1	177.1	52.0	2.0
Selling, General & Administrative Expenses (SG&A)	121.4	69.5	106.4	61.9	103.4	182.0	182.8	227.3	249.7	237.0
Operating Income % margin	794.3 48.1%	722.9 38.5%	939.7 58.8%	1,364.4 76.0%	2,623.2 144.6%	1,595.0 75.2%	1,430.7 62.5%	977.5 43.7%	1,492.2 63.4%	1,292.0 57.1%
Interest Income	0.0	0.0	6.8	24.4	22.3	28.4	53.5	78.3	72.3	0.0
Interest Expense	224.4	238.9	247.3	280.0	268.6	157.0	166.1	188.0	187.2	226.0
Pre-tax Income	758.7	761.9	1,343.2	1,517.9	2,461.4	1,702.0	1,241.2	230.1	1,700.1	1,331.0
Income Tax % effective tax rate	177.3 23.4%	196.0 25.7%	542.7 40.4%	433.4 28.6%	349.3 14.2%	1,147.0 67.4%	762.4 61.4%	187.2 81.4%	0.0 0.0%	472.0 35.5%
Net Income % margin	581.4 35.2%	565.9 30.1%	1,210.0 75.7%	1,377.7 76.8%	2,348.5 129.4%	495.2 23.3%	478.8 20.9%	42.8 1.9%	1,134.8 48.2%	859.0 37.9%
EPS	0.96	0.93	3.42	3.89	6.42	1.32	1.15	0.10	3.41	1.92
Diluted EPS	0.96	0.93	3.42	3.89	6.42	1.32	1.15	0.10	2.53	1.45
EBITDA % margin	862.4 52.2%	1,069.0 56.9%	973.0 60.9%	1,397.7 77.9%	2,647.1 145.9%	1,683.5 79.3%	1,453.7 63.5%	928.6 41.5%	1,887.3 80.2%	1,292.0 57.1%

Discover more Stock Ideas

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%

S&P Outperformance 19.1%

Next 3M Predicted Return 20.3%

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%

S&P Outperformance 22.3%

Next 3M Predicted Return 26.8%

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%

S&P Outperformance 15.4%

Next 3M Predicted Return 16.9%

More ideas -->

FAQ

1) What is Royalty Pharma plc's PEG 1Y?

As of today, Microsoft Corp's last 12-month PEG 1Y is 0.1x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual PEG 1Y for Royalty Pharma plc have been 0.4x over the past three years, and 0.3x over the past five years.

2) Is Royalty Pharma plc's PEG 1Y Good?

As of today, Royalty Pharma plc's PEG 1Y is 0.1x, which is higher than industry median of 0.0x. It indicates that Royalty Pharma plc's PEG 1Y is Bad.

3) How does Royalty Pharma plc's PEG 1Y compare to its peers?

As of today, Royalty Pharma plc's PEG 1Y is 0.1x, which is lower than peer median of 0.7x. The list of peers includes ARGX, ALNY, REGN, NVO, UTHR, BNTX, VRTX, INCY, BGNE, SMMT.

#Royalty Pharma plc PEG 1Y

#Royalty Pharma plc (RPRX) PEG 1Y comparison analysis

General

LTM PEG 1Y

OTHER METRICS

Company name

Revenue growth

EPS growth

Net Income margin

#RPRX key stats

#Discover more Stock Ideas